SANTA CLARA, Calif.--(BUSINESS WIRE)--
XenoPort, Inc. (Nasdaq:XNPT) today reminded stockholders to vote at the
Company’s upcoming Annual Meeting of Stockholders on June 11, 2014.
Time is short and stockholders are encouraged to vote the WHITE proxy
card today. XenoPort urges stockholders not to return any proxy card
sent to them by Clinton Relational Opportunity Master Fund, L.P. and its
affiliates (Clinton). Even if stockholders have already voted using the
gold proxy card, they have the right to change their vote simply by
executing and submitting the WHITE proxy card in support of
XenoPort’s director nominees. Only the last-dated proxy card will count.
Stockholders can vote by telephone or Internet according to the
instructions on the WHITE proxy card. Voting by telephone or
Internet is the best way to ensure that votes will be counted.
Two independent proxy advisory firms, Institutional Shareholder
Services (ISS) and Egan-Jones Proxy Services (Egan-Jones), have
recommended that XenoPort stockholders vote on the WHITE proxy card “FOR
ALL” of XenoPort’s director nominees: Ronald W. Barrett,
Ph.D., Jeryl L. Hilleman and Wendell Wierenga, Ph.D.
XenoPort also urges stockholders to vote "FOR" the approval
of the XenoPort, Inc. 2014 Equity Incentive Plan, vote "FOR"
the approval, on an advisory basis, of the compensation of XenoPort's
named executive officers, and vote "FOR" the ratification of
the selection by the audit committee of the Board of Directors of Ernst
& Young LLP as XenoPort's independent registered public accounting firm
for the fiscal year ending December 31, 2014. In addition, the XenoPort
Board urges stockholders to vote "FOR" Proposals 9 through
14 and "AGAINST" Clinton Proposals 5 through 8.
If you have any questions, require assistance with voting your WHITE
card or need additional copies of the proxy materials, please contact:
MACKENZIE PARTNERS, INC.
105 Madison Avenue
New York, NY 10016
(212) 929-5500 (Call Collect)
TOLL-FREE (800) 322-2885
Important Additional Information and Where to
XenoPort, Inc., its directors and certain of its executive officers may
be deemed to be participants in the solicitation of proxies from
stockholders in connection with XenoPort's 2014 Annual Meeting of
Stockholders. XenoPort has filed with the SEC and provided to its
stockholders a definitive proxy statement and a WHITE proxy
card in connection with such solicitation. XENOPORT STOCKHOLDERS ARE
STRONGLY ENCOURAGED TO READ THE PROXY STATEMENT (INCLUDING ANY
AMENDMENTS AND SUPPLEMENTS) AND THE ACCOMPANYING WHITE PROXY
CARD, AND ANY OTHER RELEVANT DOCUMENTS WHEN THEY BECOME AVAILABLE,
BECAUSE THEY CONTAIN IMPORTANT INFORMATION.
Information regarding the names of XenoPort's directors and executive
officers and their respective interests in XenoPort by security holdings
or otherwise is set forth in XenoPort's definitive proxy statement for
the 2014 Annual Meeting of Stockholders, filed with the SEC on April 22,
2014, including Appendix B thereto.
The definitive proxy statement (and amendments or supplements thereto)
and the accompanying WHITE proxy card, and any other
relevant documents and other material filed by XenoPort with the SEC,
are or will be available for no charge at the SEC's website at www.sec.gov and
at XenoPort's investor relations website at http://investor.xenoport.com/index.cfm.
Copies may also be obtained free of charge by contacting
XenoPort Investor Relations by mail at 3410 Central Expressway, Santa
Clara, California 95051 or by telephone at (408) 616-7200.
XenoPort, Inc. is a biopharmaceutical company focused on developing and
commercializing a portfolio of internally discovered product candidates
for the potential treatment of neurological disorders. XenoPort is
currently commercializing HORIZANT® (gabapentin enacarbil)
Extended-Release Tablets in the United States and developing its novel
fumaric acid ester product candidate, XP23829, as a potential treatment
for psoriasis and/or relapsing forms of multiple sclerosis. REGNITE®
(gabapentin enacarbil) Extended-Release Tablets is being marketed
in Japan by Astellas Pharma Inc. XenoPort's pipeline of product
candidates also includes a potential treatment for patients with
Parkinson's disease. To learn more about XenoPort, please visit the Web
site at www.XenoPort.com.
HORIZANT, REGNITE and XENOPORT are registered trademarks of XenoPort,
Jackie Cossmon, 408-616-7220
Source: XenoPort, Inc.